Success Metrics

Clinical Success Rate
50.0%

Based on 4 completed trials

Completion Rate
50%(4/8)
Active Trials
1(11%)
Results Posted
100%(4 trials)
Terminated
4(44%)

Phase Distribution

Ph phase_1
6
67%
Ph phase_2
2
22%
Ph phase_3
1
11%

Phase Distribution

6

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(4)
Terminated(4)

Detailed Status

Completed4
Terminated4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (66.7%)
Phase 22 (22.2%)
Phase 31 (11.1%)

Trials by Status

active_not_recruiting111%
completed444%
terminated444%

Recent Activity

1 active trials
Showing 5 of 9
active_not_recruitingphase_1

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

NCT03283137
terminatedphase_3

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

NCT02612311
completedphase_1

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

NCT02268851
completedphase_1

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

NCT02493530
terminatedphase_2

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

NCT03207256
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03283137Phase 1

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

Active Not Recruiting
NCT02612311Phase 3

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Terminated
NCT02268851Phase 1

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Completed
NCT02493530Phase 1

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Completed
NCT03207256Phase 2

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Terminated
NCT01767766Phase 1

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Completed
NCT02867618Phase 1

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Terminated
NCT03178201Phase 2

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Terminated
NCT02574663Phase 1

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9